CAM
VRTX icon

Cidel Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cidel Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Buy
766
+87
+13% +$38.6K 0.02% 311
2026
Q1 		$303K Buy
679
+147
+28% +$68.5K 0.02% 318
2025
Q4 		$241K Buy
+532
New +$229K 0.02% 319

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Cidel Asset Management's VRTX Position: Q2 2026 in Review

Cidel Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, buying an estimated $38.6K and bringing the position to 766 shares worth $381K. The position accounts for 0.02% of the portfolio, ranked #311.

Cidel Asset Management first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cidel Asset Management held 766 shares of Vertex Pharmaceuticals worth $381K as of Q2 2026.
  • Cidel Asset Management bought 87 Vertex Pharmaceuticals shares in Q2 2026, an estimated $38.6K.
  • Vertex Pharmaceuticals made up 0.02% of Cidel Asset Management's portfolio in Q2 2026, its #311 holding.
  • Cidel Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cidel Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.